KYTX Long Call Strategy

KYTX (Kyverna Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019.

KYTX (Kyverna Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $472.1M, a beta of 2.06 versus the broader market, a 52-week range of 2.06-13.67, average daily share volume of 851K, a public-listing history dating back to 2024, approximately 112 full-time employees. These structural characteristics shape how KYTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.06 indicates KYTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on KYTX?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current KYTX snapshot

As of May 13, 2026, spot at $10.66, ATM IV 68.50%, IV rank 5.12%, expected move 19.64%. The long call on KYTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 36-day expiry.

Why this long call structure on KYTX specifically: KYTX IV at 68.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a KYTX long call, with a market-implied 1-standard-deviation move of approximately 19.64% (roughly $2.09 on the underlying). The 36-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KYTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on KYTX should anchor to the underlying notional of $10.66 per share and to the trader's directional view on KYTX stock.

KYTX long call setup

The KYTX long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KYTX near $10.66, the first option leg uses a $10.66 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KYTX chain at a 36-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KYTX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$10.66N/A

KYTX long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

KYTX long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on KYTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on KYTX

Long calls on KYTX express a bullish thesis with defined risk; traders use them ahead of KYTX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

KYTX thesis for this long call

The market-implied 1-standard-deviation range for KYTX extends from approximately $8.57 on the downside to $12.75 on the upside. A KYTX long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current KYTX IV rank near 5.12% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on KYTX at 68.50%. As a Healthcare name, KYTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KYTX-specific events.

KYTX long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KYTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KYTX alongside the broader basket even when KYTX-specific fundamentals are unchanged. Long-premium structures like a long call on KYTX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current KYTX chain quotes before placing a trade.

Frequently asked questions

What is a long call on KYTX?
A long call on KYTX is the long call strategy applied to KYTX (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With KYTX stock trading near $10.66, the strikes shown on this page are snapped to the nearest listed KYTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are KYTX long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the KYTX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 68.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a KYTX long call?
The breakeven for the KYTX long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KYTX market-implied 1-standard-deviation expected move is approximately 19.64%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on KYTX?
Long calls on KYTX express a bullish thesis with defined risk; traders use them ahead of KYTX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current KYTX implied volatility affect this long call?
KYTX ATM IV is at 68.50% with IV rank near 5.12%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related KYTX analysis